Medical device design & development, answered.

Most devices move through eight stages: concept and user needs, feasibility, design and development, verification and validation, clinical evidence, regulatory submission, design transfer to manufacturing, and launch and scale. Each stage answers a specific question and produces evidence the next stage depends on. Our MedTech Process guide walks through each one.

It depends mostly on risk class and regulatory pathway. Simple Class I or 510(k)-exempt products can reach market in roughly 12 to 24 months. Many Class II devices cleared through a 510(k) take two to four years from concept. Novel De Novo devices and Class III PMA devices that need significant clinical data commonly take five years or more. Our free Journey Planner estimates a timeline for your device and stage.

Costs range from a few hundred thousand dollars for simple, low-risk devices to several million for typical 510(k) programs and tens of millions for PMA devices with pivotal clinical trials. The biggest drivers are the regulatory pathway, the amount of clinical evidence, device complexity (electronics, software, implants) and how many design iterations are needed. Spending to the next value milestone, rather than building the whole company at once, keeps capital working.

Earlier than most founders think, ideally once the clinical need is clear and before the design is locked. A partner with regulatory and manufacturing experience can shape the architecture so you avoid redesigns later. Many engagements start small: a feasibility sprint, a design review or a prototype build, then grow as the program proves out.

Not always, but investors increasingly fund de-risked programs. A functional prototype with bench data on the riskiest questions, early clinician feedback and a credible regulatory and manufacturing plan makes a much stronger case than a concept alone.

It is Birch Design’s structured review of where your program stands across design, regulatory, clinical, quality and manufacturing. You receive a prioritized gap list and a practical roadmap you can execute or share with investors. It suits founders with a concept, prototype, feasibility data or early clinical direction. Request one here.

Under the Federal Food, Drug, and Cosmetic Act, a product intended to diagnose, cure, mitigate, treat or prevent disease, or to affect the structure or function of the body, without achieving its main purpose through chemical action or metabolism, is generally a medical device. Intended use and marketing claims matter as much as the technology, and some software functions also qualify.

FDA classifies devices by risk. Class I devices are low risk and most are exempt from premarket review. Class II devices are moderate risk and usually require a 510(k). Class III devices are high risk, often life-sustaining or implantable, and usually require Premarket Approval (PMA). Classification drives the evidence, cost and timeline of the whole program.

A 510(k) shows your device is substantially equivalent to a legally marketed predicate device; FDA’s review goal is 90 FDA days. A De Novo request is for novel low-to-moderate risk devices with no predicate; the goal is 150 FDA days. A PMA is for Class III devices and usually requires pivotal clinical data; the goal is 180 FDA days, longer with an advisory panel. “FDA days” exclude time spent waiting on your responses.

A predicate is a legally marketed device that a 510(k) compares your device against to show it has the same intended use and similar technological characteristics, or that differences do not raise new questions of safety and effectiveness. Choosing the right predicate is a strategic decision that shapes your testing plan.

A Pre-Submission is a free request for written FDA feedback on your planned pathway, testing or clinical study before you submit. FDA typically responds about 70 days after receiving it, with an optional meeting. It is one of the most cost-effective ways for a startup to replace regulatory assumptions with FDA’s view.

FDA’s Quality Management System Regulation (QMSR) took effect on February 2, 2026 and incorporates ISO 13485:2016 by reference, aligning U.S. quality requirements with the international standard. Early-stage companies don’t need a heavyweight system, but design controls and document control should start as soon as you generate evidence you will rely on for submission.

For FDA fiscal year 2027 (October 1, 2026 to September 30, 2027) the standard fees are $28,653 for a 510(k), $191,020 for a De Novo request and $636,732 for a PMA. Qualifying small businesses (generally $100 million or less in gross receipts) pay $7,163, $47,755 and $159,183. The annual establishment registration fee is $13,785. Source: Federal Register.

Design controls are the documented process for developing a device: user needs, design inputs, design outputs, design reviews, verification, validation, design transfer and change control, all captured in a design history file. They show FDA how you know the device is safe and effective, and they keep teams from losing track of why decisions were made.

Verification asks “did we build the device right?” by testing that design outputs meet design inputs (for example, tensile strength or battery life). Validation asks “did we build the right device?” by confirming the finished device meets user needs in its intended use, often through simulated-use or human factors testing.

Most devices with user interaction benefit from it, and many submissions require it. Formative studies during development uncover use errors early; a summative (validation) study on production-equivalent devices shows critical tasks can be performed safely. FDA guidance and IEC 62366-1 describe the process.

Devices that contact the body need an evaluation, under ISO 10993-1, of whether materials could cause harm such as cytotoxicity, sensitization or irritation. The tests required depend on the type and duration of contact. Selecting proven materials early can reduce testing scope and cost.

At the concept stage. ISO 14971 risk management identifies hazards, estimates and controls risks and runs through the full life of the device. Early risk analysis directly shapes the design inputs and the verification plan, so starting late usually means rework.

Roughly speaking, the design determines most of a product’s cost. A prototype that works when hand-built can be expensive or inconsistent in production. Reviewing tolerances, materials, assembly steps, packaging and sterilization before design freeze protects margins and avoids repeating verification testing.

Many 510(k) devices are cleared on bench, animal and usability data alone. De Novo requests often include some clinical data, and PMAs almost always require a pivotal clinical study. A Pre-Submission is the best way to confirm what FDA will expect for your device.

An IDE allows an investigational device to be used in a U.S. clinical study. Significant-risk studies need FDA approval of an IDE plus IRB approval; non-significant-risk studies generally need IRB approval only. Planning device builds, labeling and quality documentation for the study is part of clinical readiness.

Usually bench testing first to answer engineering questions cheaply, then cadaver or anatomical-model work to evaluate usability and access, then animal studies for safety and performance in living tissue when required, and finally human studies. Each study should have a clear question and a result that would change the plan.

Start conversations during design and development, and select a partner before design freeze when possible. Early input on processes, tooling and cost lets the manufacturer help shape the design, and it avoids a rushed selection when verification builds are due.

Define what you actually need (development, transfer, testing or production), build a short list through trusted referrals, then evaluate technical fit (similar products, the right processes, documentation and scale) and working fit (communication, responsiveness, transparency and ownership). Understand each manufacturer’s business model and how your product fits it. See our selection guide.

Design transfer converts a verified design into repeatable production: manufacturing processes, work instructions, fixtures and tooling, supplier qualification and process validation (IQ, OQ and PQ). A clean transfer is what lets a manufacturer build the same device every time at the target cost.

Automation pays off when volumes are predictable, the design is stable and manual processes limit quality, throughput or cost. Planning automation readiness early, such as features for fixturing and inspection, makes the step much cheaper when demand arrives.

Sterile devices need a validated sterile barrier system (ISO 11607) and a validated sterilization process such as ethylene oxide or radiation. Packaging and sterilization choices affect materials, shelf-life testing and cost, so they belong in the design phase, not after it.

Most startups combine them. Fractional experts and consultants give flexibility early; development firms bring broad capability for complex builds; contract manufacturers bring production infrastructure as the design matures; full-time hires make sense once the product and funding are stable. Start lean and add infrastructure as confidence grows.

Time and materials fits early work where the scope is still evolving. Defined milestones fit work with a clear deliverable. Fractional or retained support gives continuity without a full-time hire. Development-plus-manufacturing agreements fit when a partner also has production capability. Many strong relationships start with one small, clearly defined project.

We typically start with a discovery call and a Readiness Assessment, then support the program through targeted projects, milestone programs or fractional program leadership, from product design and FDA strategy to design transfer and contract manufacturer selection. We bring a network of trusted suppliers, test labs and manufacturers.

Yes. Birch Design is based in the Twin Cities in Minnesota’s Medical Alley and works with medical device startups and companies across the United States.

Schedule a discovery call, email j.burich@birch-design.com, or try the Journey Planner first and bring your results to the conversation.